Clinical Trials Logo

Gamification clinical trials

View clinical trials related to Gamification.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06402942 Recruiting - Clinical trials for Duchenne Muscular Dystrophy

Gamified Occupational Therapy for Adolescents With Duchenne Muscular Dystrophy

DMD
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

This research aims to improve the quality of life, occupational performance, occupational satisfaction and emotional health of young people with Duchenne muscular dystrophy compared to the classical occupational therapy program. The findings are planned to shed light on the development of new and effective strategies in the rehabilitation of adolescents with Duchenne muscular dystrophy.

NCT ID: NCT05725330 Recruiting - Type 2 Diabetes Clinical Trials

The Effect of Gamification on Patients With Type 2 Diabetes

Start date: February 25, 2023
Phase: N/A
Study type: Interventional

Diabetes is a broad-spectrum metabolic disorder that causes a defect in the organism's carbohydrate, fat, and protein metabolism processes due to insulin deficiency or impaired insulin effect. Diabetes requires continuous medical care and causes chronic, severe mortality and morbidity. More than 90% of all people with diabetes worldwide suffer from Type 2 DM. Diabetes self-management includes self-monitoring of blood glucose levels, knowing and managing the symptoms of hypoglycemia and hyperglycemia, adherence to diet, physical exercise, and diabetic foot care. Considering the high prevalent and undesirable consequences of diabetes in the world, it is necessary to benefit from new educational technologies and tools. One of these technologies is gamification, which increases the quality of education as an effective educational tool, creates motivation and enthusiasm, and develops a sense of competition in the target audience. This study plans to develop a game that will include virtual coaching to increase the self-management and glycemic control of patients with type 2 diabetes.